<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html lang="en">

<head>
  <title>Doxorubicin and Cyclophosphamide Plus Paclitaxel With or Without Trastuzumab in Treating Women With Node-Positive Breast Cancer That Overexpresses HER2 - Full Text View - ClinicalTrials.gov</title>
    <meta http-equiv="Content-Type" content="text/html;charset=UTF-8"/>
    <link href="/ct2/show/NCT00004067" rel="canonical"/>
    <link href="/ct2/html/images/frame/icon.ico" rel="SHORTCUT ICON"/>
  <link href="/ct2/html/images/frame/ct.css" type="text/css" rel="stylesheet"/>
  <script type="text/javascript" src="/ct2/html/images/frame/ct.js" language="JavaScript"></script>
  <script type="text/javascript" src="/ct2/html/images/foresee/foresee-trigger.js"></script>
</head>

<body style="min-width:720px; margin-left:0px; margin-right:0px; margin-top:0px" onload="doLoadActions();">

<!-- small_banner -->
<div class="skip"><a href="#MainContent">Skip to Main Content</a></div>

<table class="layout_table banner_color" cellspacing="0" cellpadding="0" border="0" width="100%">
  <tr>
    <td align="left" style="padding:6px" nowrap>
      <a title="Show Home Page" href="/ct2/home">
        <img alt="ClinicalTrials.gov" src="/ct2/html/images/frame/small_title.gif" border="0"/>
      </a>
    </td>

    <td class="header3" align="right" style="padding:3px 12px 3px 3px;" nowrap>
            <a style="margin-left:1em;" title="Show Home Page" href="/ct2/home">Home</a>
            <a style="margin-left:1em;" title="Show Search Page" href="/ct2/search">Search</a>
            <a style="margin-left:1em;" title="Show Study Topics Page" href="/ct2/search/browse">Study Topics</a>
            <a style="margin-left:1em;" title="Show Glossary Page" href="/ct2/info/glossary">Glossary</a>
            <br/>
      <form method="get" action="/ct2/results" style="margin-top:0.5ex; margin-bottom:0px;">
        <input class="body3" type="text" name="term" alt="Quick Search" title="Quick Search" value="" size="30" maxlength="250"/>
        <input class="header3" type="submit" alt="Search" value="Search"/>
        
      </form>
    </td>
  </tr>
</table>

<img width="100%" height="3" src="/ct2/html/images/frame/bar.gif" alt=""/><br/>

<a name="MainContent" id="skipnav"></a>


<!-- above_tabs -->
<div class="show_back_color">
<br/>


</div>








<!-- tabs -->
<div class="show_back_color header3">
<table class="layout_table" cellpadding="0" cellspacing="0" border="0">
  <tr valign="bottom">
            <td valign="bottom"><img style="width:20px; height:2px" src="/ct2/html/images/tabs/top.gif" alt=""/></td>
        <td valign="bottom"><img style="width:10px; height:2px;" src="/ct2/html/images/tabs/top.gif" alt=""/></td>
            <td>
      <table class="fore_tab_color layout_table" cellpadding="0" cellspacing="0" border="0">
        <tr>
          <td class="show_back_color"><img width="6" height="6" src="/ct2/html/images/tabs/upper_left_fore.gif" alt=""/></td>
          <td valign="top"><img style="width:100%; height:2px;" src="/ct2/html/images/tabs/top.gif" alt=""/></td>
          <td class="show_back_color"><img width="6" height="6" src="/ct2/html/images/tabs/upper_right_fore.gif" alt=""/></td>
        </tr>
        <tr>
          <td align="left"><img style="width:2px; height:4ex;" src="/ct2/html/images/tabs/left.gif" alt=""/></td>
          <td valign="top" style="padding:0.5ex 1.0em" nowrap >
            <span class="header2">Full Text View</span>
          </td>
          <td align="right"><img style="width:2px; height:4ex;" src="/ct2/html/images/tabs/right.gif" alt=""/></td>
        </tr>
        <tr>
          <td align="left"><img width="1" height="2" src="/ct2/html/images/tabs/top.gif" alt=""/></td>
          <td/>
          <td align="right"><img width="2" height="2" src="/ct2/html/images/tabs/top.gif" alt=""/></td>
        </tr>
      </table>
    </td>
        <td valign="bottom"><img style="width:10px; height:2px;" src="/ct2/html/images/tabs/top.gif" alt=""/></td>
            <td>
      <table class="back_tab_color layout_table" cellpadding="0" cellspacing="0" border="0">
        <tr>
          <td class="show_back_color"><img width="6" height="6" src="/ct2/html/images/tabs/upper_left_back.gif" alt=""/></td>
          <td valign="top"><img style="width:100%; height:2px;" src="/ct2/html/images/tabs/top.gif" alt=""/></td>
          <td class="show_back_color"><img width="6" height="6" src="/ct2/html/images/tabs/upper_right_back.gif" alt=""/></td>
        </tr>
        <tr>
          <td align="left"><img style="width:2px; height:3ex;" src="/ct2/html/images/tabs/left.gif" alt=""/></td>
          <td valign="top" style="padding:0.5px 0.5em" nowrap>
            <a title="Show Tabular View Page" href="/ct2/show/record/NCT00004067" >Tabular View</a>
          </td>
          <td align="right"><img style="width:2px; height:3ex;" src="/ct2/html/images/tabs/right.gif" alt=""/></td>
        </tr>
        <tr>
          <td valign="top" colspan="3"><img width="100%" height="2" src="/ct2/html/images/tabs/top.gif" alt=""/></td>
        </tr>
      </table>
    </td>
        <td valign="bottom"><img style="width:10px; height:2px;" src="/ct2/html/images/tabs/top.gif" alt=""/></td>
            <td>
      <table class="back_tab_color layout_table" cellpadding="0" cellspacing="0" border="0">
        <tr>
          <td class="show_back_color"><img width="6" height="6" src="/ct2/html/images/tabs/upper_left_back.gif" alt=""/></td>
          <td valign="top"><img style="width:100%; height:2px;" src="/ct2/html/images/tabs/top.gif" alt=""/></td>
          <td class="show_back_color"><img width="6" height="6" src="/ct2/html/images/tabs/upper_right_back.gif" alt=""/></td>
        </tr>
        <tr>
          <td align="left"><img style="width:2px; height:3ex;" src="/ct2/html/images/tabs/left.gif" alt=""/></td>
          <td valign="top" style="padding:0.5px 0.5em" nowrap>
            <a title="Show No Study Results Posted Page" href="/ct2/show/results/NCT00004067"  style="color:#666666" >No Study Results Posted</a>
          </td>
          <td align="right"><img style="width:2px; height:3ex;" src="/ct2/html/images/tabs/right.gif" alt=""/></td>
        </tr>
        <tr>
          <td valign="top" colspan="3"><img width="100%" height="2" src="/ct2/html/images/tabs/top.gif" alt=""/></td>
        </tr>
      </table>
    </td>
        <td valign="bottom"><img style="width:10px; height:2px;" src="/ct2/html/images/tabs/top.gif" alt=""/></td>
            <td valign="bottom"><img style="width:50px; height:2px" src="/ct2/html/images/tabs/top.gif" alt=""/></td>
        <td valign="bottom"><img style="width:10px; height:2px;" src="/ct2/html/images/tabs/top.gif" alt=""/></td>
            <td>
      <table class="back_tab_color layout_table" cellpadding="0" cellspacing="0" border="0">
        <tr>
          <td class="show_back_color"><img width="6" height="6" src="/ct2/html/images/tabs/upper_left_back.gif" alt=""/></td>
          <td valign="top"><img style="width:100%; height:2px;" src="/ct2/html/images/tabs/top.gif" alt=""/></td>
          <td class="show_back_color"><img width="6" height="6" src="/ct2/html/images/tabs/upper_right_back.gif" alt=""/></td>
        </tr>
        <tr>
          <td align="left"><img style="width:2px; height:3ex;" src="/ct2/html/images/tabs/left.gif" alt=""/></td>
          <td valign="top" style="padding:0.5px 0.5em" nowrap>
            <a title="Show Related Studies Page" href="/ct2/show/related/NCT00004067" >Related Studies</a>
          </td>
          <td align="right"><img style="width:2px; height:3ex;" src="/ct2/html/images/tabs/right.gif" alt=""/></td>
        </tr>
        <tr>
          <td valign="top" colspan="3"><img width="100%" height="2" src="/ct2/html/images/tabs/top.gif" alt=""/></td>
        </tr>
      </table>
    </td>
        <td valign="bottom"><img style="width:10px; height:2px;" src="/ct2/html/images/tabs/top.gif" alt=""/></td>
        <td valign="bottom" width="100%"><img style="width:100%; height:2px" src="/ct2/html/images/tabs/top.gif" alt=""/></td>
  </tr>
</table>
</div>

<!-- Title section -->
<div class="indent3" align="center">

    <div class="header1" style="margin-top:3ex;">Doxorubicin and Cyclophosphamide Plus Paclitaxel With or Without Trastuzumab in Treating Women With Node-Positive Breast Cancer That Overexpresses HER2</div>
  
   
      
        <div class="header2" style="margin-top:2ex; color:  red  ">
      This study is ongoing, but not recruiting participants.
    </div>
        
        
      
    
  <br/>
  <div>
    First Received on December 10, 1999. &nbsp;
          Last Updated on December 16, 2010 &nbsp;
      <a href="/ct2/archive/NCT00004067"
        title="Historical versions of study NCT00004067 on ClinicalTrials.gov Archive Site"
        onclick="openNewWindow('/ct2/archive/NCT00004067'); return false;">History of Changes</a>
      </div>

  <table class="data_table" cellspacing="0" cellpadding="5" border="1" width="50%" style="margin:2ex 0;">

        <tr>
      <th align="right" nowrap class="header3 pale_banner_color"> Sponsor: </th>
      <td align="left" nowrap class="body2"> National Surgical Adjuvant Breast and Bowel Project (NSABP) </td>
    </tr>
    
        <tr>
      <th align="right" nowrap class="header3 pale_banner_color">
         Collaborator:       </th>
      <td align="left" nowrap class="body2">
                                         <a href="/ct2/bye/7QoPWw4lZX-i-iSxuBc5udNzlXNiZiJ." onclick="openNewWindow('/ct2/bye/7QoPWw4lZX-i-iSxuBc5udNzlXNiZiJ.'); return false">National Cancer Institute (NCI)</a><br/>               </td>
    </tr>
    
        <tr>
      <th align="right" nowrap class="header3 pale_banner_color">Information provided by: </th>
      <td align="left" nowrap class="body2">National Surgical Adjuvant Breast and Bowel Project (NSABP)</td>
    </tr>
    
    <tr>
      <th align="right" nowrap class="header3 pale_banner_color">ClinicalTrials.gov Identifier: </th>
      <td align="left" nowrap class="body2">NCT00004067</td>
    </tr>

  </table>

</div>
  
<!-- purpose_section -->
<div class="indent1" style="margin-top:3ex">
<img src="/ct2/html/images/frame/triangle.gif" alt=""/><span class="header2">&nbsp; Purpose</span>

<div class="indent2" style="margin-top:2ex">

  <div class="body3"><p style="margin-top:0ex; margin-bottom:1ex;">RATIONALE: Drugs used in chemotherapy, such as doxorubicin, cyclophosphamide, and paclitaxel, use different ways to stop tumor cells from dividing so they stop growing or die. Monoclonal antibodies such as trastuzumab can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. It is not yet known whether combination chemotherapy plus trastuzumab is more effective than combination chemotherapy alone for treating breast cancer.</p>
<p style="margin-top:0ex; margin-bottom:1ex;">PURPOSE: This randomized phase III trial is studying how well giving combination chemotherapy together with trastuzumab works compared to combination chemotherapy alone in treating women with node-positive stage II or stage IIIA breast cancer that overexpresses HER2.</p></div><br/>

    <!-- condition, intervention, phase summary table -->
  <div align="center">
  <table class="data_table" cellspacing="0" cellpadding="5" border="1" width="80%">
    <tr align="left">
            <th class="header3 pale_banner_color">
        <a href="/ct2/help/conditions_desc" title="Help on Conditions field" onclick="openPopupWindow('/ct2/help/conditions_desc',false); return false;">Condition</a>
      </th>
                  <th class="header3 pale_banner_color">
        <a href="/ct2/help/interventions_desc" title="Help on Interventions field" onclick="openPopupWindow('/ct2/help/interventions_desc',false); return false;">Intervention</a>
      </th>
                  <th class="header3 pale_banner_color">
        <a href="/ct2/help/phase_desc" title="Help on Phase field" onclick="openPopupWindow('/ct2/help/phase_desc',false); return false;">Phase</a>
      </th>
          </tr>
    <tr align="left" valign="top">
            <td class="body3" nowrap>
                Breast Cancer<br/>
              </td>
                  <td class="body3" nowrap>
                Biological: trastuzumab<br/>
                Drug: AC-T regimen<br/>
                Drug: cyclophosphamide<br/>
                Drug: doxorubicin hydrochloride<br/>
                Drug: endocrine-modulating drug therapy<br/>
                Drug: paclitaxel<br/>
                Drug: tamoxifen citrate<br/>
                Radiation: radiation therapy<br/>
              </td>
                  <td class="body3" nowrap>
                Phase III<br/>
              </td>
          </tr>
  </table>
  </div>
  <br/>
  
  
  <table class="layout_table" style="margin-bottom:2ex;" cellpadding="0" cellspacing="0" border="0">
        <tr valign="top">
      <td nowrap>Study Type:</td>
      <td style="padding-left:1em">
        Interventional
              </td>
    </tr>
            <tr valign="top">
      <td nowrap>Study Design:</td>
      <td style="padding-left:1em">Allocation:&#160;Randomized<br/>Primary&#160;Purpose:&#160;Treatment</td>
    </tr>
            <tr valign="top">
      <td nowrap style="padding-top:2ex">Official Title:</td>
      <td style="padding-left:1em; padding-top:2ex">A Randomized Trial Comparing the Safety and Efficacy of Adriamycin and Cyclophosphamide Followed by Taxol (AC-T) to That of Adriamycin and Cyclophosphamide Followed by Taxol Plus Herceptin (AC-T+H) in Node-Positive Breast Cancer Patients Who Have Tumors That Overexpress HER2</td>
    </tr>
      </table>

    <!-- NLM links -->
  <br/>
  <div class="header3">Resource links provided by NLM:</div>
  <br/>
  <div class="indent3">

    <!-- ghr links -->
  <div style="margin-bottom:2ex">
    <a href="http://ghr.nlm.nih.gov/" title="Genetics Home Reference site" onclick="openNewWindow('http://ghr.nlm.nih.gov/'); return false">Genetics Home Reference</a> related topics:
            <a style="padding-left:0.5em;" href="/ct2/bye/uQoPWw4lZXcilwpxudhWudNzlXNiZip90dcx5Q1PedcOZBUyzB1gWX7gkdNgzwJ." title="breast&#160;cancer at Genetics Home Reference site" onclick="openNewWindow('/ct2/bye/uQoPWw4lZXcilwpxudhWudNzlXNiZip90dcx5Q1PedcOZBUyzB1gWX7gkdNgzwJ.'); return false">breast&#160;cancer</a>
          </div>
  
    <!-- medline links -->
  <div style="margin-bottom:2ex;">
    <a href="http://www.nlm.nih.gov/medlineplus/" title="MedlinePlus site" onclick="openNewWindow('http://www.nlm.nih.gov/medlineplus/'); return false">MedlinePlus</a> related topics:
            <a style="padding-left:0.5em;" href="/ct2/bye/WQoPWw4lZX-i-iSxudhWudNzlXNiZip9m67PvQ7xzwhaLwS9pwNHkw-P0B7x061nuQoPmdt." title="Breast&#160;Cancer at MedlinePlus site" onclick="openNewWindow('/ct2/bye/WQoPWw4lZX-i-iSxudhWudNzlXNiZip9m67PvQ7xzwhaLwS9pwNHkw-P0B7x061nuQoPmdt.'); return false">Breast&#160;Cancer</a>
                <a style="padding-left:0.5em;" href="/ct2/bye/uQoPWw4lZX-i-iSxudhWudNzlXNiZip9m67PvQ7xzwhaLwS90B7x061nuQoPmdt." title="Cancer at MedlinePlus site" onclick="openNewWindow('/ct2/bye/uQoPWw4lZX-i-iSxudhWudNzlXNiZip9m67PvQ7xzwhaLwS90B7x061nuQoPmdt.'); return false">Cancer</a>
          </div>
  
    <!-- SIS links -->
  <div style="margin-bottom:2ex;">
    <a href="http://druginfo.nlm.nih.gov/drugportal/drugportal.jsp" title="Drug Information Portal" onclick="openNewWindow('http://druginfo.nlm.nih.gov/drugportal/drugportal.jsp'); return false">Drug Information</a> available for:
            <a style="padding-left:0.5em;" href="/ct2/bye/yQoPWw4lZXcPSi7iedN6ZXNxvdDxuQ7Ju6c9cXcPSi7iEd-yWB7EZ6o35Q1yzB-VuQUgEscxkd789V-z0dh9EQh9Fwhkkd7z56V." title="Cyclophosphamide at ChemIDplus site" onclick="openNewWindow('/ct2/bye/yQoPWw4lZXcPSi7iedN6ZXNxvdDxuQ7Ju6c9cXcPSi7iEd-yWB7EZ6o35Q1yzB-VuQUgEscxkd789V-z0dh9EQh9Fwhkkd7z56V.'); return false">Cyclophosphamide</a>
                <a style="padding-left:0.5em;" href="/ct2/bye/YQoPWw4lZXcPSi7iedN6ZXNxvdDxuQ7Ju6c9cXcPSi7iEd-yWB7EZ6o35Q1yzB-VuQUgEscxkd789HhGmd-ke6NHu." title="Tamoxifen at ChemIDplus site" onclick="openNewWindow('/ct2/bye/YQoPWw4lZXcPSi7iedN6ZXNxvdDxuQ7Ju6c9cXcPSi7iEd-yWB7EZ6o35Q1yzB-VuQUgEscxkd789HhGmd-ke6NHu.'); return false">Tamoxifen</a>
                <a style="padding-left:0.5em;" href="/ct2/bye/jQoPWw4lZXcPSi7iedN6ZXNxvdDxuQ7Ju6c9cXcPSi7iEd-yWB7EZ6o35Q1yzB-VuQUgEscxkd789Ph9Od-yLBNz0Q7O." title="Doxorubicin at ChemIDplus site" onclick="openNewWindow('/ct2/bye/jQoPWw4lZXcPSi7iedN6ZXNxvdDxuQ7Ju6c9cXcPSi7iEd-yWB7EZ6o35Q1yzB-VuQUgEscxkd789Ph9Od-yLBNz0Q7O.'); return false">Doxorubicin</a>
                <a style="padding-left:0.5em;" href="/ct2/bye/DQoPWw4lZXcPSi7iedN6ZXNxvdDxuQ7Ju6c9cXcPSi7iEd-yWB7EZ6o35Q1yzB-VuQUgEscxkd789Ph9Od-yLBNz0Q7OfQoz5wN90QhaZwNz56V." title="Doxorubicin&#160;hydrochloride at ChemIDplus site" onclick="openNewWindow('/ct2/bye/DQoPWw4lZXcPSi7iedN6ZXNxvdDxuQ7Ju6c9cXcPSi7iEd-yWB7EZ6o35Q1yzB-VuQUgEscxkd789Ph9Od-yLBNz0Q7OfQoz5wN90QhaZwNz56V.'); return false">Doxorubicin&#160;hydrochloride</a>
                <a style="padding-left:0.5em;" href="/ct2/bye/4QoPWw4lZXcPSi7iedN6ZXNxvdDxuQ7Ju6c9cXcPSi7iEd-yWB7EZ6o35Q1yzB-VuQUgEscxkd7898hG0dhzWB1kzdt." title="Paclitaxel at ChemIDplus site" onclick="openNewWindow('/ct2/bye/4QoPWw4lZXcPSi7iedN6ZXNxvdDxuQ7Ju6c9cXcPSi7iEd-yWB7EZ6o35Q1yzB-VuQUgEscxkd7898hG0dhzWB1kzdt.'); return false">Paclitaxel</a>
                <a style="padding-left:0.5em;" href="/ct2/bye/IQoPWw4lZXcPSi7iedN6ZXNxvdDxuQ7Ju6c9cXcPSi7iEd-yWB7EZ6o35Q1yzB-VuQUgEscxkd789HhGmd-ke6NHuIcgeioykih8." title="Tamoxifen&#160;citrate at ChemIDplus site" onclick="openNewWindow('/ct2/bye/IQoPWw4lZXcPSi7iedN6ZXNxvdDxuQ7Ju6c9cXcPSi7iEd-yWB7EZ6o35Q1yzB-VuQUgEscxkd789HhGmd-ke6NHuIcgeioykih8.'); return false">Tamoxifen&#160;citrate</a>
                <a style="padding-left:0.5em;" href="/ct2/bye/jQoPWw4lZXcPSi7iedN6ZXNxvdDxuQ7Ju6c9cXcPSi7iEd-yWB7EZ6o35Q1yzB-VuQUgEscxkd789Hoykw-PLTUHmB7n." title="Trastuzumab at ChemIDplus site" onclick="openNewWindow('/ct2/bye/jQoPWw4lZXcPSi7iedN6ZXNxvdDxuQ7Ju6c9cXcPSi7iEd-yWB7EZ6o35Q1yzB-VuQUgEscxkd789Hoykw-PLTUHmB7n.'); return false">Trastuzumab</a>
                <a style="padding-left:0.5em;" href="/ct2/bye/oQoPWw4lZXcPSi7iedN6ZXNxvdDxuQ7Ju6c9cXcPSi7iEd-yWB7EZ6o35Q1yzB-VuQUgEscxkd7898c95Q1HmIWgeioykih8." title="Sodium&#160;Citrate at ChemIDplus site" onclick="openNewWindow('/ct2/bye/oQoPWw4lZXcPSi7iedN6ZXNxvdDxuQ7Ju6c9cXcPSi7iEd-yWB7EZ6o35Q1yzB-VuQUgEscxkd7898c95Q1HmIWgeioykih8.'); return false">Sodium&#160;Citrate</a>
          </div>
  
  <a href="/ct2/info/fdalinks" title="Show FDA resources page" onclick="openNewWindow('/ct2/info/fdalinks'); return false">U.S. FDA Resources</a>


  
  <br/>
  
  </div>
  
    <!-- more details -->
  <br/>
  <div class="header3">Further study details as provided by National Surgical Adjuvant Breast and Bowel Project (NSABP):</div>
  <br/>
  <div class="indent3">

        <!-- primary outcomes -->
    <div class="body3">Primary Outcome Measures:
      <ul style="margin-top:1ex; margin-bottom:1ex;">
            <li style="margin-top:0.7ex;">Disease Free Survival<br/>
            </ul>
    </div>
    <br/>
    
        <!-- secondary outcomes -->
    <div class="body3">Secondary Outcome Measures:
      <ul style="margin-top:1ex; margin-bottom:1ex;">
            <li style="margin-top:0.7ex;">Survival<br/>
            </ul>
    </div>
    <br/>
    
    
    <table class="layout_table" style="margin-bottom:3ex;" cellpadding="0" cellspacing="0" border="0">
            <tr valign="top">
        <td nowrap> Enrollment:</td>
        <td style="padding-left:1em">2130</td>
      </tr>
                  <tr valign="top">
        <td nowrap> Study Start Date:</td>
        <td style="padding-left:1em">February 2000</td>
      </tr>
                  <tr valign="top">
        <td nowrap> Estimated  Study Completion Date:</td>
        <td style="padding-left:1em">March 2013</td>
      </tr>
                  <tr valign="top">
        <td nowrap> Primary Completion Date:</td>
        <td style="padding-left:1em">March 2005 (Final data collection date for primary outcome measure)</td>
      </tr>
          </table>

    
    
    <a name="desc" id="desc"></a>

    
    
        <!-- detailed description -->
    <span class="header3">Detailed Description:</span>
    <div class="body3"><p style="margin-top:0ex; margin-bottom:1ex;">OBJECTIVES:</p>
<ul style="margin-top:1ex; margin-bottom:1ex;">
<li style="margin-top:0.7ex;">Compare the cardiotoxicity of doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab (Herceptin&#174;) in women with operable, node-positive breast cancer that overexpresses HER2.</li>
<li style="margin-top:0.7ex;">Compare the effect of these regimens on disease-free and overall survival of these patients.</li>
</ul>
<p style="margin-top:0ex; margin-bottom:1ex;">OUTLINE: This is a randomized, multicenter study. Patients are stratified according to number of positive nodes (1-3 vs 4-9 vs 10 or more), administration of hormonal therapy (tamoxifen vs anastrozole vs neither), surgery/radiotherapy (lumpectomy plus breast irradiation vs lumpectomy plus breast irradiation plus regional irradiation vs mastectomy without radiotherapy vs mastectomy with radiotherapy), paclitaxel schedule (every 3 weeks vs weekly), and participating center. Patients are randomized to one of two treatment arms.</p>
<ul style="margin-top:1ex; margin-bottom:1ex;">
<li style="margin-top:0.7ex;">Arm I: Patients receive doxorubicin IV and cyclophosphamide IV over 30 minutes on day 1. Treatment repeats every 21 days for 4 courses. Approximately 3 weeks after the last course, patients receive paclitaxel IV over 3 hours every 21 days for 4 courses OR paclitaxel IV over 1 hour once weekly for 12 weeks (12 doses).</li>
<li style="margin-top:0.7ex;">Arm II: Patients receive chemotherapy as in arm I and trastuzumab (Herceptin&#174;) IV over 90 minutes on day 1 of the first course of paclitaxel. Trastuzumab is then administered IV over 30 minutes weekly for 51 weeks, beginning on day 8.</li>
</ul>
<p style="margin-top:0ex; margin-bottom:1ex;">All patients with estrogen or progesterone receptor-positive tumors receive hormonal therapy* for at least 5 years, beginning within 3-12 weeks after the last dose of chemotherapy. Patients who have received prior tamoxifen for prevention may be treated with additional tamoxifen for no more than 5 years at the discretion of the principal investigator (PI).</p>
<p style="margin-top:0ex; margin-bottom:1ex;">NOTE: *Other hormonal therapeutic agents are allowed in sequence with or as an alternative to tamoxifen therapy.</p>
<p style="margin-top:0ex; margin-bottom:1ex;">All patients previously treated with lumpectomy undergo breast irradiation beginning after completion of chemotherapy and concurrently with trastuzumab (in arm II) administration. Patients previously treated with mastectomy may also receive radiotherapy. Radiotherapy is administered daily for 5-6 weeks.</p>
<p style="margin-top:0ex; margin-bottom:1ex;">Patients are followed every 6 months for 5 years and then annually thereafter.</p>
<p style="margin-top:0ex; margin-bottom:1ex;">PROJECTED ACCRUAL: A total of 2,700 patients will be accrued for this study within 4.75 years.</p></div>
        
  </div>
  
</div>
</div>
  
<!-- eligibility_section -->
<div class="indent1" style="margin-top:3ex; border:1px solid white">
  <img src="/ct2/html/images/frame/triangle.gif" alt=""/><span class="header2">&nbsp; Eligibility</span><br/>

  <br/>
  <div class="indent2">
    <table class="layout_table" cellpadding="0" cellspacing="0" border="0">
                  <tr>
        <td nowrap>Genders Eligible for Study: &nbsp; </td>
        <td style="padding-left:1em">Female</td>
      </tr>
                  <tr>
        <td nowrap>Accepts Healthy Volunteers: &nbsp; </td>
        <td style="padding-left:1em">No</td>
      </tr>
                </table>

    
        <div class="header3" style="margin-top:2ex">Criteria</div>
    <div class="indent2"><p style="margin-top:0ex; margin-bottom:1ex;">DISEASE CHARACTERISTICS:</p>
<ul style="margin-top:1ex; margin-bottom:1ex;">
<li style="margin-top:0.7ex;"><p style="margin-top:0ex; margin-bottom:1ex;">Histologically or cytologically proven invasive adenocarcinoma of the breast</p>
<ul style="margin-top:1ex; margin-bottom:1ex;">
<li style="margin-top:0.7ex;">Stage IIA, IIB, or IIIA</li>
<li style="margin-top:0.7ex;">Confined to the breast and ipsilateral axilla (cN0-1) on clinical examination</li>
<li style="margin-top:0.7ex;">At least 1 histologically positive axillary node</li>
<li style="margin-top:0.7ex;">No lymph nodes clinically fixed to each other or to other structures (cN2)</li>
<li style="margin-top:0.7ex;"><p style="margin-top:0ex; margin-bottom:1ex;">HER2 strongly positive (3+ by immunostain OR gene amplification by fluorescent in situ hybridization)</p>
<ul style="margin-top:1ex; margin-bottom:1ex;">
<li style="margin-top:0.7ex;">Submission of tumor block required</li>
</ul>
</li>
</ul>
</li>
<li style="margin-top:0.7ex;"><p style="margin-top:0ex; margin-bottom:1ex;">Must have undergone axillary dissection and either total mastectomy OR lumpectomy</p>
<ul style="margin-top:1ex; margin-bottom:1ex;">
<li style="margin-top:0.7ex;">Sentinel node dissection allowed, if followed by axillary dissection</li>
<li style="margin-top:0.7ex;">No diffuse tumors by mammography in patients treated with lumpectomy</li>
<li style="margin-top:0.7ex;">No more than 84 days since prior surgery for breast cancer (e.g., lumpectomy, mastectomy, axillary dissection, or re-excision of lumpectomy margins)</li>
</ul>
</li>
<li style="margin-top:0.7ex;">No bilateral malignancy, contralateral mass, or mammographic abnormality unless histologically proven as benign</li>
<li style="margin-top:0.7ex;">No suspicious palpable nodes in the contralateral axilla or palpable supraclavicular or infraclavicular nodes unless histologically proven not to be involved with tumor</li>
<li style="margin-top:0.7ex;">No primary T4 tumors (for any reason)</li>
<li style="margin-top:0.7ex;"><p style="margin-top:0ex; margin-bottom:1ex;">No prior breast cancer, including ductal carcinoma in situ</p>
<ul style="margin-top:1ex; margin-bottom:1ex;">
<li style="margin-top:0.7ex;">Prior lobular carcinoma in situ allowed</li>
</ul>
</li>
<li style="margin-top:0.7ex;">Bone pain allowed provided there is no metastatic disease by x-ray, MRI, or biopsy</li>
<li style="margin-top:0.7ex;"><p style="margin-top:0ex; margin-bottom:1ex;">Hormone receptor status:</p>
<ul style="margin-top:1ex; margin-bottom:1ex;">
<li style="margin-top:0.7ex;">Estrogen and progesterone status known</li>
</ul>
</li>
</ul>
<p style="margin-top:0ex; margin-bottom:1ex;">PATIENT CHARACTERISTICS:</p>
<p style="margin-top:0ex; margin-bottom:1ex;">Age:</p>
<ul style="margin-top:1ex; margin-bottom:1ex;">
<li style="margin-top:0.7ex;">Not specified</li>
</ul>
<p style="margin-top:0ex; margin-bottom:1ex;">Sex:</p>
<ul style="margin-top:1ex; margin-bottom:1ex;">
<li style="margin-top:0.7ex;">Female</li>
</ul>
<p style="margin-top:0ex; margin-bottom:1ex;">Menopausal status:</p>
<ul style="margin-top:1ex; margin-bottom:1ex;">
<li style="margin-top:0.7ex;">Not specified</li>
</ul>
<p style="margin-top:0ex; margin-bottom:1ex;">Performance status:</p>
<ul style="margin-top:1ex; margin-bottom:1ex;">
<li style="margin-top:0.7ex;">Not specified</li>
</ul>
<p style="margin-top:0ex; margin-bottom:1ex;">Life expectancy:</p>
<ul style="margin-top:1ex; margin-bottom:1ex;">
<li style="margin-top:0.7ex;">At least 10 years, excluding diagnosis of breast cancer</li>
</ul>
<p style="margin-top:0ex; margin-bottom:1ex;">Hematopoietic:</p>
<ul style="margin-top:1ex; margin-bottom:1ex;">
<li style="margin-top:0.7ex;">Platelet count at least 100,000/mm^3*</li>
<li style="margin-top:0.7ex;">Absolute neutrophil count at least 1,500/mm^3 (unless determined by the investigator to be normal for ethnic or racial variation) NOTE: *Significant underlying hematologic disorders must be excluded if above upper limit of normal (ULN)</li>
</ul>
<p style="margin-top:0ex; margin-bottom:1ex;">Hepatic:</p>
<ul style="margin-top:1ex; margin-bottom:1ex;">
<li style="margin-top:0.7ex;">Bilirubin no greater than ULN</li>
<li style="margin-top:0.7ex;">SGOT less than 1.5 times ULN</li>
<li style="margin-top:0.7ex;">Alkaline phosphatase less than 2.5 times ULN</li>
<li style="margin-top:0.7ex;">No systemic hepatic disease that would preclude study participation</li>
</ul>
<p style="margin-top:0ex; margin-bottom:1ex;">Renal:</p>
<ul style="margin-top:1ex; margin-bottom:1ex;">
<li style="margin-top:0.7ex;">Creatinine normal</li>
<li style="margin-top:0.7ex;">No systemic renal disease that would preclude study participation</li>
</ul>
<p style="margin-top:0ex; margin-bottom:1ex;">Cardiovascular:</p>
<ul style="margin-top:1ex; margin-bottom:1ex;">
<li style="margin-top:0.7ex;">LVEF at least lower limit of normal by MUGA</li>
<li style="margin-top:0.7ex;">No cardiovascular disease that would preclude study participation</li>
<li style="margin-top:0.7ex;">No angina pectoris requiring treatment</li>
<li style="margin-top:0.7ex;">No cardiomegaly on chest x-ray</li>
<li style="margin-top:0.7ex;">No prior myocardial infarction by clinical diagnosis or by EKG or other test</li>
<li style="margin-top:0.7ex;">No prior congestive heart failure</li>
<li style="margin-top:0.7ex;">No prior cardiomyopathy</li>
<li style="margin-top:0.7ex;">No cardiac arrhythmia requiring medication</li>
<li style="margin-top:0.7ex;">No severe conduction abnormality</li>
<li style="margin-top:0.7ex;">No clinically significant valvular disease</li>
<li style="margin-top:0.7ex;">No poorly controlled hypertension (diastolic greater than 100 mm Hg), unless adequately controlled by medication</li>
<li style="margin-top:0.7ex;">No ventricular hypertrophy on EKG</li>
</ul>
<p style="margin-top:0ex; margin-bottom:1ex;">Other:</p>
<ul style="margin-top:1ex; margin-bottom:1ex;">
<li style="margin-top:0.7ex;">Not pregnant or nursing</li>
<li style="margin-top:0.7ex;">Fertile patients must use effective barrier contraception</li>
<li style="margin-top:0.7ex;">No other prior malignancy within the past 5 years except effectively treated carcinoma in situ of the cervix, melanoma in situ, or basal cell or squamous cell skin cancer</li>
<li style="margin-top:0.7ex;">No psychiatric or addictive disorders that would preclude informed consent</li>
<li style="margin-top:0.7ex;">No sensory or motor neuropathy grade 2 or greater</li>
<li style="margin-top:0.7ex;">No contraindications to corticosteroids</li>
</ul>
<p style="margin-top:0ex; margin-bottom:1ex;">PRIOR CONCURRENT THERAPY:</p>
<p style="margin-top:0ex; margin-bottom:1ex;">Biologic therapy:</p>
<ul style="margin-top:1ex; margin-bottom:1ex;">
<li style="margin-top:0.7ex;">No prior biologic therapy for this breast cancer</li>
</ul>
<p style="margin-top:0ex; margin-bottom:1ex;">Chemotherapy:</p>
<ul style="margin-top:1ex; margin-bottom:1ex;">
<li style="margin-top:0.7ex;">No prior chemotherapy for this breast cancer</li>
<li style="margin-top:0.7ex;">No prior anthracycline or taxane therapy for any cancer</li>
</ul>
<p style="margin-top:0ex; margin-bottom:1ex;">Endocrine therapy:</p>
<ul style="margin-top:1ex; margin-bottom:1ex;">
<li style="margin-top:0.7ex;">No prior hormonal therapy for this breast cancer</li>
<li style="margin-top:0.7ex;">No concurrent hormonal therapy (e.g., birth control pills or ovarian hormone replacement therapy)</li>
<li style="margin-top:0.7ex;">No concurrent raloxifene or other selective estrogen-receptor modulators</li>
</ul>
<p style="margin-top:0ex; margin-bottom:1ex;">Radiotherapy:</p>
<ul style="margin-top:1ex; margin-bottom:1ex;">
<li style="margin-top:0.7ex;">No prior radiotherapy for this breast cancer</li>
<li style="margin-top:0.7ex;">No concurrent radiotherapy to internal mammary nodes</li>
<li style="margin-top:0.7ex;">No other concurrent radiotherapy except as specified in study</li>
</ul>
<p style="margin-top:0ex; margin-bottom:1ex;">Surgery:</p>
<ul style="margin-top:1ex; margin-bottom:1ex;">
<li style="margin-top:0.7ex;">See Disease Characteristics</li>
</ul>
<p style="margin-top:0ex; margin-bottom:1ex;">Other:</p>
<ul style="margin-top:1ex; margin-bottom:1ex;">
<li style="margin-top:0.7ex;">No other concurrent investigational agents</li>
</ul></div>
    
  </div>

</div>

  
<!-- location_section -->
<div class="indent1" style="margin-top:3ex">
<img src="/ct2/html/images/frame/triangle.gif" alt=""/><span class="header2">&nbsp; Contacts and Locations</span><br/>

<div class="indent2" style="margin-top:2ex">

    Please refer to this study by its ClinicalTrials.gov identifier: NCT00004067<br/>
  <br/>

  <!-- contacts -->
  
  <!-- locations -->
  <a name="locn" id="locn"></a>

    <img style="float:left" border="0" src="/ct2/html/images/frame/plus.gif" alt=""/>&nbsp;
  <a class="header3" title="Show 149 study locations" href="/ct2/show/study/NCT00004067?show_locs=Y#locn">Show 149 Study Locations</a><br/>

  
  <!-- sponsors -->
    <div class="header3" style="margin-top:2ex">Sponsors and Collaborators</div>
    <div class="indent2" style="margin-top:1ex">National Surgical Adjuvant Breast and Bowel Project (NSABP)</div>
    <div class="indent2" style="margin-top:1ex"><a href="/ct2/bye/7QoPWw4lZX-i-iSxuBc5udNzlXNiZiJ." onclick="openNewWindow('/ct2/bye/7QoPWw4lZX-i-iSxuBc5udNzlXNiZiJ.'); return false">National Cancer Institute (NCI)</a></div>
    
  <!-- investigators -->
    <div class="header3" style="margin-top:2ex">Investigators</div>
  <table class="layout_table indent2" cellspacing="0" cellpadding="0" border="0">
        <tr>
      <td style="padding:1ex 1em 0px 0px" nowrap>Study Chair:</td>
      <td style="padding:1ex 1em 0px 0px" nowrap>Edward H. Romond, MD</td>
            <td style="padding:1ex 1em 0px 0px" nowrap>Lucille P. Markey Cancer Center at University of Kentucky</td>
                </tr>
      </table>
  

</div>
</div>

<!-- more_info_section -->
<div class="indent1" style="margin-top:3ex; border:1px solid white">
<img src="/ct2/html/images/frame/triangle.gif" alt=""/><span class="header2">&nbsp; More Information</span>

<div class="indent2">
  <br/>


    Additional Information:
    <div class="indent2" style="margin-top:2ex">
        <a href="/ct2/bye/fQoPWw4lZXcgkdNgzwpxUd-BZBcaedNz0B7aWwNzkdoRZCzg3VztmVpWFRV/IVcaedNz0B7EJioyeB7EJw-Hmd7GSTD3NwN9mnoPl6D3KB1PedcxkdY34B7x061nJD7xFihzWi1Pzy-RJ8jPPE_OJ6hGWB7ykwc8" title="Clinical trial summary from the National Cancer Institute's PDQ&#174; database" onclick="openNewWindow('/ct2/bye/fQoPWw4lZXcgkdNgzwpxUd-BZBcaedNz0B7aWwNzkdoRZCzg3VztmVpWFRV/IVcaedNz0B7EJioyeB7EJw-Hmd7GSTD3NwN9mnoPl6D3KB1PedcxkdY34B7x061nJD7xFihzWi1Pzy-RJ8jPPE_OJ6hGWB7ykwc8'); return false">Clinical trial summary from the National Cancer Institute's PDQ&#174; database</a>&nbsp
    <img src="/ct2/html/images/frame/exit.bmp" alt="This link exits the ClinicalTrials.gov site"/>
      </div>
    <br/>
  
    Publications:
  <div class="indent2">
            <div style="margin-top:2ex">
            Rastogi P, Jeong J, Geyer CE, et al.: Five year update of cardiac dysfunction on NSABP B-31, a randomized trial of sequential doxorubicin/cyclophosphamide (AC)&#8594;paclitaxel (T) vs. AC&#8594;T with trastuzumab(H). [Abstract] J Clin Oncol 25 (Suppl 18): A-LBA513, 2007.
          </div>
        <div style="margin-top:2ex">
            Geyer CE, Bryant JL, Romond EH, et al.: Update of cardiac dysfunction on NSABP B-31, a randomized trial of sequential doxorubicin/cyclophosphamide (AC)&#8594;paclitaxel (T) vs. AC&#8594;T with trastuzumab (H). [Abstract] J Clin Oncol 24 (Suppl 18): A-581, 2006.
          </div>
        <div style="margin-top:2ex">
            Kim C, Bryant J, Horne Z, et al.: Trastuzumab sensitivity of breast cancer with co-amplification of HER2 and cMYC suggests pro-apoptotic function of dysregulated cMYC in vivo. [Abstract] Breast Cancer Research and Treatment 94 (Suppl 1): A-46, 2005.
          </div>
        <div style="margin-top:2ex">
            <a href="/ct2/bye/zQoPWw4lZX-i-iSxuBcyeXNxvdDxuQ7Ju6c9cXcHuioyzTp9ai7HSTDxNBciescgm64LD61PSQ7Hc6D65B0LVi7yg67VN6h9Ei4L3BUgWwNG0iY6vQ1gW1-He6oR9RCBSgCJEK4R." title="Tan-Chiu E, Yothers G, Romond E, Geyer CE Jr, Ewer M, Keefe D, Shannon RP, Swain SM, Brown A, Fehrenbacher L, Vogel VG, Seay TE, Rastogi P, Mamounas EP, Wolmark N, Bryant J. Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31. J Clin Oncol. 2005 Nov 1;23(31):7811-9." onclick="openNewWindow('/ct2/bye/zQoPWw4lZX-i-iSxuBcyeXNxvdDxuQ7Ju6c9cXcHuioyzTp9ai7HSTDxNBciescgm64LD61PSQ7Hc6D65B0LVi7yg67VN6h9Ei4L3BUgWwNG0iY6vQ1gW1-He6oR9RCBSgCJEK4R.'); return false">Tan-Chiu E, Yothers G, Romond E, Geyer CE Jr, Ewer M, Keefe D, Shannon RP, Swain SM, Brown A, Fehrenbacher L, Vogel VG, Seay TE, Rastogi P, Mamounas EP, Wolmark N, Bryant J. Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31. J Clin Oncol. 2005 Nov 1;23(31):7811-9.</a>
          </div>
        <div style="margin-top:2ex">
            Geyer CE Jr, Bryant J, Romond E: Cardiac safety analysis of the first stage of NSABP B-31, a randomized trial comparing the safety and efficacy of adriamycin&#174; and cyclophosphamide (AC) followed by taxol&#174; to that of AC followed by taxol&#174; plus herceptin&#174; in patients (Pts) with operable, node-positive (N+), HER-2 overexpressing breast cancer (HER2+BC). [Abstract] Breast Cancer Res Treat 82 (Suppl 1): A-23, S13, 2003.
          </div>
        <div style="margin-top:2ex">
            <a href="/ct2/bye/zQoPWw4lZX-i-iSxuBcyeXNxvdDxuQ7Ju6c9cXcHuioyzTp9ai7HSTDxNBciescgm64LD61PSQ7Hc6D65B0LVi7yg67VN6h9Ei4L3BUgWwNG0iY6vQ1gW1-He6oR9RCnEg4JSgFR." title="Paik S, Bryant J, Tan-Chiu E, Romond E, Hiller W, Park K, Brown A, Yothers G, Anderson S, Smith R, Wickerham DL, Wolmark N. Real-world performance of HER2 testing--ational Surgical Adjuvant Breast and Bowel Project experience. J Natl Cancer Inst. 2002 Jun 5;94(11):852-4." onclick="openNewWindow('/ct2/bye/zQoPWw4lZX-i-iSxuBcyeXNxvdDxuQ7Ju6c9cXcHuioyzTp9ai7HSTDxNBciescgm64LD61PSQ7Hc6D65B0LVi7yg67VN6h9Ei4L3BUgWwNG0iY6vQ1gW1-He6oR9RCnEg4JSgFR.'); return false">Paik S, Bryant J, Tan-Chiu E, Romond E, Hiller W, Park K, Brown A, Yothers G, Anderson S, Smith R, Wickerham DL, Wolmark N. Real-world performance of HER2 testing--ational Surgical Adjuvant Breast and Bowel Project experience. J Natl Cancer Inst. 2002 Jun 5;94(11):852-4.</a>
          </div>
                    <div style="margin-top:2ex">
            <a href="/ct2/bye/zQoPWw4lZX-i-iSxuBcyeXNxvdDxuQ7Ju6c9cXcHuioyzTp9ai7HSTDxNBciescgm64LD61PSQ7Hc6D65B0LVi7yg67VN6h9Ei4L3BUgWwNG0iY6vQ1gW1-He6oR9RCJ-gCwSgC5." title="Jahanzeb M. Adjuvant trastuzumab therapy for HER2-positive breast cancer. Clin Breast Cancer. 2008 Aug;8(4):324-33." onclick="openNewWindow('/ct2/bye/zQoPWw4lZX-i-iSxuBcyeXNxvdDxuQ7Ju6c9cXcHuioyzTp9ai7HSTDxNBciescgm64LD61PSQ7Hc6D65B0LVi7yg67VN6h9Ei4L3BUgWwNG0iY6vQ1gW1-He6oR9RCJ-gCwSgC5.'); return false">Jahanzeb M. Adjuvant trastuzumab therapy for HER2-positive breast cancer. Clin Breast Cancer. 2008 Aug;8(4):324-33.</a>
          </div>
        <div style="margin-top:2ex">
            Reinholz MM, Dueck AC, Lingle WL, et al.: The concordance between NCCTG's and NSABP's C-myc FISH assays. [Abstract] J Clin Oncol 26 (Suppl 15): A-22110, 2008.
          </div>
        <div style="margin-top:2ex">
            <a href="/ct2/bye/zQoPWw4lZX-i-iSxuBcyeXNxvdDxuQ7Ju6c9cXcHuioyzTp9ai7HSTDxNBciescgm64LD61PSQ7Hc6D65B0LVi7yg67VN6h9Ei4L3BUgWwNG0iY6vQ1gW1-He6oR9RCwLKCnOR0w." title="Garrison LP Jr, Lubeck D, Lalla D, Paton V, Dueck A, Perez EA. Cost-effectiveness analysis of trastuzumab in the adjuvant setting for treatment of HER2-positive breast cancer. Cancer. 2007 Jun 25; [Epub ahead of print]" onclick="openNewWindow('/ct2/bye/zQoPWw4lZX-i-iSxuBcyeXNxvdDxuQ7Ju6c9cXcHuioyzTp9ai7HSTDxNBciescgm64LD61PSQ7Hc6D65B0LVi7yg67VN6h9Ei4L3BUgWwNG0iY6vQ1gW1-He6oR9RCwLKCnOR0w.'); return false">Garrison LP Jr, Lubeck D, Lalla D, Paton V, Dueck A, Perez EA. Cost-effectiveness analysis of trastuzumab in the adjuvant setting for treatment of HER2-positive breast cancer. Cancer. 2007 Jun 25; [Epub ahead of print]</a>
          </div>
        <div style="margin-top:2ex">
            <a href="/ct2/bye/zQoPWw4lZX-i-iSxuBcyeXNxvdDxuQ7Ju6c9cXcHuioyzTp9ai7HSTDxNBciescgm64LD61PSQ7Hc6D65B0LVi7yg67VN6h9Ei4L3BUgWwNG0iY6vQ1gW1-He6oR9RCwFR4JSg0J." title="Kurian AW, Thompson RN, Gaw AF, Arai S, Ortiz R, Garber AM. A cost-effectiveness analysis of adjuvant trastuzumab regimens in early HER2/neu-positive breast cancer. J Clin Oncol. 2007 Feb 20;25(6):634-41." onclick="openNewWindow('/ct2/bye/zQoPWw4lZX-i-iSxuBcyeXNxvdDxuQ7Ju6c9cXcHuioyzTp9ai7HSTDxNBciescgm64LD61PSQ7Hc6D65B0LVi7yg67VN6h9Ei4L3BUgWwNG0iY6vQ1gW1-He6oR9RCwFR4JSg0J.'); return false">Kurian AW, Thompson RN, Gaw AF, Arai S, Ortiz R, Garber AM. A cost-effectiveness analysis of adjuvant trastuzumab regimens in early HER2/neu-positive breast cancer. J Clin Oncol. 2007 Feb 20;25(6):634-41.</a>
          </div>
        <div style="margin-top:2ex">
            <a href="/ct2/bye/zQoPWw4lZX-i-iSxuBcyeXNxvdDxuQ7Ju6c9cXcHuioyzTp9ai7HSTDxNBciescgm64LD61PSQ7Hc6D65B0LVi7yg67VN6h9Ei4L3BUgWwNG0iY6vQ1gW1-He6oR9RCwFR4JSg0w." title="Liberato NL, Marchetti M, Barosi G. Cost effectiveness of adjuvant trastuzumab in human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol. 2007 Feb 20;25(6):625-33." onclick="openNewWindow('/ct2/bye/zQoPWw4lZX-i-iSxuBcyeXNxvdDxuQ7Ju6c9cXcHuioyzTp9ai7HSTDxNBciescgm64LD61PSQ7Hc6D65B0LVi7yg67VN6h9Ei4L3BUgWwNG0iY6vQ1gW1-He6oR9RCwFR4JSg0w.'); return false">Liberato NL, Marchetti M, Barosi G. Cost effectiveness of adjuvant trastuzumab in human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol. 2007 Feb 20;25(6):625-33.</a>
          </div>
        <div style="margin-top:2ex">
            Perez E, Romond E, Suman V, et al.: Updated results of the combined analysis of NCCTG N9831 and NSABP B-31 adjuvant chemotherapy with/without trastuzumab in patiens with HER2-positive breast cancer. [Abstract] J Clin Oncol 25 (Suppl 18): 512, 6s, 2007.
          </div>
        <div style="margin-top:2ex">
            <a href="/ct2/bye/zQoPWw4lZX-i-iSxuBcyeXNxvdDxuQ7Ju6c9cXcHuioyzTp9ai7HSTDxNBciescgm64LD61PSQ7Hc6D65B0LVi7yg67VN6h9Ei4L3BUgWwNG0iY6vQ1gW1-He6oR9RCwcK4wagCw." title="Telli ML, Hunt SA, Carlson RW, Guardino AE. Trastuzumab-related cardiotoxicity: calling into question the concept of reversibility. J Clin Oncol. 2007 Aug 10;25(23):3525-33." onclick="openNewWindow('/ct2/bye/zQoPWw4lZX-i-iSxuBcyeXNxvdDxuQ7Ju6c9cXcHuioyzTp9ai7HSTDxNBciescgm64LD61PSQ7Hc6D65B0LVi7yg67VN6h9Ei4L3BUgWwNG0iY6vQ1gW1-He6oR9RCwcK4wagCw.'); return false">Telli ML, Hunt SA, Carlson RW, Guardino AE. Trastuzumab-related cardiotoxicity: calling into question the concept of reversibility. J Clin Oncol. 2007 Aug 10;25(23):3525-33.</a>
          </div>
        <div style="margin-top:2ex">
            <a href="/ct2/bye/zQoPWw4lZX-i-iSxuBcyeXNxvdDxuQ7Ju6c9cXcHuioyzTp9ai7HSTDxNBciescgm64LD61PSQ7Hc6D65B0LVi7yg67VN6h9Ei4L3BUgWwNG0iY6vQ1gW1-He6oR9RCBxgFj-RFV." title="Baselga J, Perez EA, Pienkowski T, Bell R. Adjuvant trastuzumab: a milestone in the treatment of HER-2-positive early breast cancer. Oncologist. 2006;11 Suppl 1:4-12. Review." onclick="openNewWindow('/ct2/bye/zQoPWw4lZX-i-iSxuBcyeXNxvdDxuQ7Ju6c9cXcHuioyzTp9ai7HSTDxNBciescgm64LD61PSQ7Hc6D65B0LVi7yg67VN6h9Ei4L3BUgWwNG0iY6vQ1gW1-He6oR9RCBxgFj-RFV.'); return false">Baselga J, Perez EA, Pienkowski T, Bell R. Adjuvant trastuzumab: a milestone in the treatment of HER-2-positive early breast cancer. Oncologist. 2006;11 Suppl 1:4-12. Review.</a>
          </div>
        <div style="margin-top:2ex">
            Garrison LP, Perez EA, Dueck A, et al.: Cost-effectiveness analysis of trastuzumab in the adjuvant setting for treatment of HER2+ breast cancer. [Abstract] J Clin Oncol 24 (Suppl 18): A-6023, 306s, 2006.
          </div>
        <div style="margin-top:2ex">
            Gupta AK, Mekan SF, Eckman MH: Trastuzumab for all? A decision analysis examining tradeoffs between efficacy and cardiac toxicity of adjuvant therapy in HER2 positive breast cancer. [Abstract] J Clin Oncol 24 (Suppl 18): A-6022, 306s, 2006.
          </div>
        <div style="margin-top:2ex">
            <a href="/ct2/bye/zQoPWw4lZX-i-iSxuBcyeXNxvdDxuQ7Ju6c9cXcHuioyzTp9ai7HSTDxNBciescgm64LD61PSQ7Hc6D65B0LVi7yg67VN6h9Ei4L3BUgWwNG0iY6vQ1gW1-He6oR9RCBSRFB-RF8." title="Burstein HJ. The distinctive nature of HER2-positive breast cancers. N Engl J Med. 2005 Oct 20;353(16):1652-4. No abstract available." onclick="openNewWindow('/ct2/bye/zQoPWw4lZX-i-iSxuBcyeXNxvdDxuQ7Ju6c9cXcHuioyzTp9ai7HSTDxNBciescgm64LD61PSQ7Hc6D65B0LVi7yg67VN6h9Ei4L3BUgWwNG0iY6vQ1gW1-He6oR9RCBSRFB-RF8.'); return false">Burstein HJ. The distinctive nature of HER2-positive breast cancers. N Engl J Med. 2005 Oct 20;353(16):1652-4. No abstract available.</a>
          </div>
        <div style="margin-top:2ex">
            <a href="/ct2/bye/zQoPWw4lZX-i-iSxuBcyeXNxvdDxuQ7Ju6c9cXcHuioyzTp9ai7HSTDxNBciescgm64LD61PSQ7Hc6D65B0LVi7yg67VN6h9Ei4L3BUgWwNG0iY6vQ1gW1-He6oR9RCBSRFB-g48." title="Hortobagyi GN. Trastuzumab in the treatment of breast cancer. N Engl J Med. 2005 Oct 20;353(16):1734-6. No abstract available." onclick="openNewWindow('/ct2/bye/zQoPWw4lZX-i-iSxuBcyeXNxvdDxuQ7Ju6c9cXcHuioyzTp9ai7HSTDxNBciescgm64LD61PSQ7Hc6D65B0LVi7yg67VN6h9Ei4L3BUgWwNG0iY6vQ1gW1-He6oR9RCBSRFB-g48.'); return false">Hortobagyi GN. Trastuzumab in the treatment of breast cancer. N Engl J Med. 2005 Oct 20;353(16):1734-6. No abstract available.</a>
          </div>
        <div style="margin-top:2ex">
            <a href="/ct2/bye/zQoPWw4lZX-i-iSxuBcyeXNxvdDxuQ7Ju6c9cXcHuioyzTp9ai7HSTDxNBciescgm64LD61PSQ7Hc6D65B0LVi7yg67VN6h9Ei4L3BUgWwNG0iY6vQ1gW1-He6oR9RCBSRFB-RFJ." title="Romond EH, Perez EA, Bryant J, Suman VJ, Geyer CE Jr, Davidson NE, Tan-Chiu E, Martino S, Paik S, Kaufman PA, Swain SM, Pisansky TM, Fehrenbacher L, Kutteh LA, Vogel VG, Visscher DW, Yothers G, Jenkins RB, Brown AM, Dakhil SR, Mamounas EP, Lingle WL, Klein PM, Ingle JN, Wolmark N. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med. 2005 Oct 20;353(16):1673-84." onclick="openNewWindow('/ct2/bye/zQoPWw4lZX-i-iSxuBcyeXNxvdDxuQ7Ju6c9cXcHuioyzTp9ai7HSTDxNBciescgm64LD61PSQ7Hc6D65B0LVi7yg67VN6h9Ei4L3BUgWwNG0iY6vQ1gW1-He6oR9RCBSRFB-RFJ.'); return false">Romond EH, Perez EA, Bryant J, Suman VJ, Geyer CE Jr, Davidson NE, Tan-Chiu E, Martino S, Paik S, Kaufman PA, Swain SM, Pisansky TM, Fehrenbacher L, Kutteh LA, Vogel VG, Visscher DW, Yothers G, Jenkins RB, Brown AM, Dakhil SR, Mamounas EP, Lingle WL, Klein PM, Ingle JN, Wolmark N. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med. 2005 Oct 20;353(16):1673-84.</a>
          </div>
        <div style="margin-top:2ex">
            <a href="/ct2/bye/zQoPWw4lZX-i-iSxuBcyeXNxvdDxuQ7Ju6c9cXcHuioyzTp9ai7HSTDxNBciescgm64LD61PSQ7Hc6D65B0LVi7yg67VN6h9Ei4L3BUgWwNG0iY6vQ1gW1-He6oR9RCnWR0nEgCB." title="Tan-Chiu E, Piccart M. Moving forward: Herceptin in the adjuvant setting. Oncology. 2002;63 Suppl 1:57-63. Review." onclick="openNewWindow('/ct2/bye/zQoPWw4lZX-i-iSxuBcyeXNxvdDxuQ7Ju6c9cXcHuioyzTp9ai7HSTDxNBciescgm64LD61PSQ7Hc6D65B0LVi7yg67VN6h9Ei4L3BUgWwNG0iY6vQ1gW1-He6oR9RCnWR0nEgCB.'); return false">Tan-Chiu E, Piccart M. Moving forward: Herceptin in the adjuvant setting. Oncology. 2002;63 Suppl 1:57-63. Review.</a>
          </div>
        <div style="margin-top:2ex">
            <a href="/ct2/bye/zQoPWw4lZX-i-iSxuBcyeXNxvdDxuQ7Ju6c9cXcHuioyzTp9ai7HSTDxNBciescgm64LD61PSQ7Hc6D65B0LVi7yg67VN6h9Ei4L3BUgWwNG0iY6vQ1gW1-He6oR9R0tFgCjEgFn." title="Costa RB, Kurra G, Greenberg L, Geyer CE. Efficacy and cardiac safety of adjuvant trastuzumab-based chemotherapy regimens for HER2-positive early breast cancer. Ann Oncol. 2010 Nov;21(11):2153-60. Epub 2010 Mar 29." onclick="openNewWindow('/ct2/bye/zQoPWw4lZX-i-iSxuBcyeXNxvdDxuQ7Ju6c9cXcHuioyzTp9ai7HSTDxNBciescgm64LD61PSQ7Hc6D65B0LVi7yg67VN6h9Ei4L3BUgWwNG0iY6vQ1gW1-He6oR9R0tFgCjEgFn.'); return false">Costa RB, Kurra G, Greenberg L, Geyer CE. Efficacy and cardiac safety of adjuvant trastuzumab-based chemotherapy regimens for HER2-positive early breast cancer. Ann Oncol. 2010 Nov;21(11):2153-60. Epub 2010 Mar 29.</a>
          </div>
          </div>
  <br/>
  
  
  
  <table class="layout_table" style="margin-top:1ex" cellpadding="0" cellspacing="0" border="0">
        <tr valign="top">
      <td nowrap>Responsible Party:</td>
      <td style="padding-left:1em">NSABP Foundation, Inc. ( Norman Wolmark, MD )</td>
    </tr>
        <tr valign="top">
      <td nowrap>ClinicalTrials.gov Identifier:</td>
      <td style="padding-left:1em">
        <a title="Current version of study NCT00004067 on ClinicalTrials.gov" href="http://clinicaltrials.gov/ct2/show/NCT00004067">NCT00004067</a> &nbsp; &nbsp;
        <a href="/ct2/archive/NCT00004067"
          title="Historical versions of study NCT00004067 on ClinicalTrials.gov Archive Site"
          onclick="openNewWindow('/ct2/archive/NCT00004067'); return false;">History of Changes</a>
      </td>
    </tr>
            <tr valign="top">
      <td nowrap>Other Study ID Numbers:</td>
      <td style="padding-left:1em">NSABP B-31, CDR0000067269</td>
    </tr>
            <tr valign="top">
      <td nowrap>Study First Received:</td>
      <td style="padding-left:1em">December 10, 1999</td>
    </tr>
                <tr valign="top">
      <td nowrap>Last Updated:</td>
      <td style="padding-left:1em">December 16, 2010</td>
    </tr>
            <tr valign="top">
      <td nowrap>Health Authority:</td>
      <td style="padding-left:1em">United States: Federal Government</td>
    </tr>
      </table>

  
  <!-- keywords -->
    <br/>
  Keywords provided by National Surgical Adjuvant Breast and Bowel Project (NSABP):
  <div class="indent3">
    <table class="layout_table" cellpadding="0" cellspacing="0" border="0" width="100%">
      <tr valign="top">
        <td width="50%">
                    stage II breast cancer<br/>
                    stage IIIA breast cancer<br/>
                  </td>
              </tr>
    </table>
  </div>
  
  <!-- mesh terms -->
    <br/>
  Additional relevant MeSH terms:
  <div class="indent3">
    <table class="layout_table" cellpadding="0" cellspacing="0" border="0" width="100%">
      <tr valign="top">
        <td width="50%">
                    Breast Neoplasms<br/>
                    Neoplasms by Site<br/>
                    Neoplasms<br/>
                    Breast Diseases<br/>
                    Skin Diseases<br/>
                    Cyclophosphamide<br/>
                    Trastuzumab<br/>
                    Doxorubicin<br/>
                    Tamoxifen<br/>
                    Paclitaxel<br/>
                    Immunosuppressive Agents<br/>
                    Immunologic Factors<br/>
                    Physiological Effects of Drugs<br/>
                    Pharmacologic Actions<br/>
                    Antirheumatic Agents<br/>
                  </td>
                <td width="50%" style="padding-left:1em">
                    Therapeutic Uses<br/>
                    Antineoplastic Agents, Alkylating<br/>
                    Alkylating Agents<br/>
                    Molecular Mechanisms of Pharmacological Action<br/>
                    Antineoplastic Agents<br/>
                    Myeloablative Agonists<br/>
                    Antibiotics, Antineoplastic<br/>
                    Antineoplastic Agents, Hormonal<br/>
                    Selective Estrogen Receptor Modulators<br/>
                    Estrogen Receptor Modulators<br/>
                    Hormone Antagonists<br/>
                    Hormones, Hormone Substitutes, and Hormone Antagonists<br/>
                    Bone Density Conservation Agents<br/>
                    Estrogen Antagonists<br/>
                    Tubulin Modulators<br/>
                  </td>
              </tr>
    </table>
  </div>
  
  
  <br/>

    <span class="body3">ClinicalTrials.gov processed this record on May 09, 2011</span><br/>
  
  <br/>

</div>
</div>


<!-- Footer -->
<div class="skip"><a href="#MainContent">Back to top of Main Content</a></div>

<img width="100%" height="3" src="/ct2/html/images/frame/bar.gif" alt=""/><br/>

<div align="center" class="footer">
  <br/>
  <a href="/ct2/helpdesk?hd_url=http%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT00004067" onclick="openPopupWindow('/ct2/helpdesk?hd_url=http%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT00004067',true); return false;">Contact Help Desk</a><br/>
  <a href="http://www.lhncbc.nlm.nih.gov">Lister Hill National Center for Biomedical Communications</a>,&nbsp;
  <a href="http://www.nlm.nih.gov/">U.S. National Library of Medicine</a>,<br/>
  <a href="http://www.nih.gov/">U.S. National Institutes of Health</a>,&nbsp;
  <a href="http://www.hhs.gov/">U.S. Department of Health &amp; Human Services</a>,<br/>
  <a href="http://www.usa.gov/">USA.gov</a>,&nbsp;
  <a href="http://www.nlm.nih.gov/copyright.html">Copyright</a>,&nbsp;
  <a href="http://www.nlm.nih.gov/privacy.html">Privacy</a>,&nbsp;
  <a href="http://www.nlm.nih.gov/accessibility.html">Accessibility</a>,&nbsp;
  <a href="http://www.nih.gov/icd/od/foia/index.htm">Freedom of Information Act</a><br/>

  <br/>
  <a href="http://www.nih.gov/"><img alt="U.S. National Institutes of Health" src="/ct2/html/images/frame/nih_logo.gif" border="0"/></a>
  <a href="http://www.nlm.nih.gov/"><img alt="U.S. National Library of Medicine" src="/ct2/html/images/frame/nlm_logo.gif" border="0"/></a>
  <a href="http://www.hhs.gov/"><img alt="U.S. Department of Health &amp; Human Services" src="/ct2/html/images/frame/hhs_logo.gif" border="0"/></a>

  <br/>
  <br/>
  <br/>
  <br/>
  <a href="/ct2/crawl" class="skip">Links to all studies - primarily for crawlers</a>
</div>

<!-- 2011:05:10 18:20:05.405  RRd0LgA:SRd0Hod:I8PKGqB -->
</body>
</html>
